Trillium Stent Graft for Leaky Heart Valve
Part of Heart & circulation clinical trials.
This trial tests a new stent graft device (Trillium) placed through a vein to help fix a severely leaky tricuspid valve without open-heart surgery. It is for people with severe symptoms who cannot have or have not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe or greater tricuspid regurgitation (a leaky heart valve).
- Your central venous pressure (pressure in the large veins near the heart) is at least 15 mmHg.
- You have significant symptoms like shortness of breath or fatigue with very little activity (NYHA class III or IV).
- You are not eligible for standard heart surgery or treatment for this condition, or you have refused it, or you've had treatment but still have symptoms.
- You do not have severe right heart weakness, high blood pressure in the lungs, or other serious heart valve or kidney/liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
This trial tests a catheter-based procedure (done through the blood vessels) to repair a severely leaky tricuspid valve. It may help people with symptoms or past hospitalizations from tricuspid valve leakage who are higher-risk for standard surgery.
This trial tests a new catheter-based device to replace your tricuspid valve without open-heart surgery. It's for people with severe tricuspid regurgitation who are at high risk for surgery.
This study tests a new catheter-based device to repair a leaky tricuspid heart valve (tricuspid regurgitation) in people who still have symptoms like shortness of breath or swelling despite taking heart medications. The goal is to see if the procedure is safe and can help reduce the leak.
This trial is testing a new, less-invasive device to fix the tricuspid valve in the heart for people with severe leakage. It may be an option if you are not a good candidate for traditional open-heart surgery and have tried other treatments.
This trial tests a new device called Laplace TTVR to replace a leaky tricuspid valve in the heart without open surgery. It is for people with severe symptoms despite medical treatment.
Hear when a new Tricuspid Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.